Target intelligence / Profile preview

Zinc finger protein 384 (ZNF384)

Target
ZNF384
Molecular classification
Transcription factor, Cys2His2-type zinc finger protein, Nuclear matrix protein
01

Overview

Zinc finger protein 384 (ZNF384) is a C2H2-type zinc finger protein that functions as a transcription factor involved in the regulation of genes important for extracellular matrix remodeling, such as MMP1, MMP3, MMP7, and COL1A1[1][2]. The protein is encoded by the ZNF384 gene, which contains long CAG trinucleotide repeats encoding consecutive glutamine residues. ZNF384 directly promotes the transcription of Cyclin D1, thereby facilitating cell cycle progression and cell proliferation. Clinically, it is implicated in cancer biology: ZNF384 overexpression is associated with poor prognosis and increased recurrence in hepatocellular carcinoma, and recurrent gene rearrangements involving ZNF384 (notably fusions with EWSR1, TAF15, and TCF3) are observed in acute leukemias, defining specific disease subtypes and playing roles in leukemogenesis[1][2][3]. ZNF384 serves as both a potential prognostic marker and a novel therapeutic target in certain cancers, though no specific drugs or mechanisms of action targeting ZNF384 are currently established in clinical practice[3][2].

Other names
TNRC1CAGH1CIZNMP4Nuclear matrix protein 4NPCAG repeat protein 1CAS-interacting zinc finger proteinNuclear matrix transcription factor 4Trinucleotide repeat-containing gene 1 proteinCAGH1AERDA2expanded repeat domainCAG/CTG 2
02

Biological functions

Transcriptional regulationRegulation of extracellular matrix genesCell proliferationCell cycle progression (G1/S transition)Positive regulation of Cyclin D1 expression
03

Disease associations

Cancer (notably acute leukemia and hepatocellular carcinoma)Potential oncogenic fusion proteinPrognostic marker in hepatocellular carcinoma
04

Safety considerations

Potential oncogenicityPrognostic implications (association with recurrence and poor survival in HCC)Genomic instability due to gene fusions
05

Biomarkers

Overexpression correlates with poor prognosis in hepatocellular carcinomaZNF384 gene rearrangements (notably fusions) serve as subtypes in acute leukemia

Beyond the preview

Go deeper on Zinc finger protein 384 (ZNF384).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zinc finger protein 384 (ZNF384).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call